Sustained Clinical Response to 4th-Line Therapy with Selpercatinib in RET Fusion-Positive Combined Small Cell Lung Cancer
Yan Huang,Shuang Dai,Wenlian Yin,Feng Luo,Yan Li
DOI: https://doi.org/10.2147/ott.s440610
IF: 4
2023-11-30
OncoTargets and Therapy
Abstract:Yan Huang, 1, 2, &ast Shuang Dai, 1, 2, &ast Wenlian Yin, 3 Feng Luo, 1, 2 Yan Li 2, 4 1 Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, People's Republic of China; 2 Lung Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, People's Republic of China; 3 Department of Pathology, West China Hospital, Sichuan University, Chengdu, Sichuan, People's Republic of China; 4 Department of Radiation Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, People's Republic of China &astThese authors contributed equally to this work Correspondence: Yan Li, Department of Radiation Oncology, Cancer Center, West China Hospital, Sichuan University, No. 37, Guo Xue Xiang, Chengdu, Sichuan, 610041, People's Republic of China, Email Objective: Combined small cell lung cancer (C-SCLC) is a relatively rare subtype of small cell lung cancer (SCLC) which combines SCLC and any component of non-small cell carcinoma (NSCLC). Patients diagnosed with C-SCLC are currently recommended to receive the same treatment as SCLC cases in the absence of clear evidence suggesting different strategies. The genomic profiling of C-SCLC is rarely studied. Herein, we report a case of extensive-stage C-SCLC harboring the KIF5B-RET fusion before first-line therapy and with persistent sensitivity to fourth-line selpercatinib treatment is reported. Materials and Methods: Molecular and pathological features were evaluated using transbronchial lung biopsy, immunohistochemical (IHC) staining and next-generation sequencing (NGS). Results: NGS revealed the KIF5B-RET fusion in the C-SCLC tumor. The patient had a progression-free survival (PFS) surpassing 14 months after selpercatinib treatment, with ongoing clinical response in 4th-line treatment. Conclusion: This case highlights the importance of comprehensive molecular testing in C-SCLC for selecting the optimal treatment. Although RET fusion is rare in patients with C-SCLC, its identification and treatment with selective RET inhibitors may contribute to clinical benefits. Keywords: combined small cell lung cancer, rearranged during transfection, selpercatinib, next-generation sequencing The 2021 WHO classification categorizes neuroendocrine neoplasms (NENs) of the lung as a single tumor group, which includes low- and intermediate-grade typical carcinoid (TC) and atypical carcinoid (AC) and high-grade NE carcinomas (NECs), including large cell neuroendocrine carcinoma (LCNEC) and small cell lung cancer (SCLC). 1 Combined small cell lung cancer (C-SCLC) is a subtype of SCLC that comprises three types according to the different components combined with SCLC, including adenocarcinoma, LCNEC, and squamous cell carcinoma. Indeed, approximately 5–28% of surgically resected SCLCs are diagnosed as C-SCLCs. 2,3 However, limited specimens, such as those obtained for cytology or from a small biopsy, tend to underestimate C-SCLC incidence. The current guidelines for SCLC management do not describe a standard treatment for C-SCLC in detail. Routinely, C-SCLC management consists of multimodality treatment (surgery, radiotherapy, chemotherapy, and immunotherapy) and is often based on SCLC guidelines. 4 To date, genomic changes in C-SCLC remain unclear, and RET fusions in C-SCLC have not been reported. The RET proto-oncogene is located on the long arm of chromosome 10 with a length of 60,000 bp and 21 exons. 5 The RET gene promotes carcinogenesis primarily by gene fusion, point mutation, and amplification, and is associated with multiple cancers. 6 RET fusions have been detected in most papillary thyroid carcinomas and in 1–2% of NSCLCs. 7,8 RET fusions involve different fusion partners, with the most common being KIF5B-RET (62–68.2%) and CCDC6-5B (16.8–21%). 9–12 Currently, the tyrosine kinase inhibitors (TKIs) selpercatinib and pralsetinib have been approved by the FDA for locally advanced or metastatic solid tumors with RET fusions that have progressed on or following prior systemic treatment. 13,14 Furthermore, several strategies and novel targeted drugs are currently under investigation. 15 Here, we report for the first time a case of extensive-stage C-SCLC, in which the tumor harbored the KIF5B-RET fusion before first-line therapy and was persistently sensitive to selpercatinib after failed cytotoxic chemotherapy, immunochemotherapy and anlotinib hydrochloride administration. This case highlights the importance of comprehensive molecular testing in C-SCLC for selecting t -Abstract Truncated-
oncology,biotechnology & applied microbiology